Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What condition primarily benefits from sapropterin therapy?
How much is mebendazole?
Mebendazole 100mg price?
What's the recommended schedule for lurbinectedin side effect checks?
Drugpatentwatch evista historical sales market context?

Can you list the primary bacterial infections treated by tigecycline?

See the DrugPatentWatch profile for tigecycline

The Broad-Spectrum Antibiotic: Understanding Tigecycline's Primary Bacterial Infections

Tigecycline, a broad-spectrum antibiotic, has revolutionized the treatment of various bacterial infections. As a derivative of tetracycline, it has a unique mechanism of action that makes it effective against a wide range of pathogens. delve into the primary bacterial infections treated by tigecycline, exploring its efficacy and limitations.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic, a class of compounds that are structurally related to tetracyclines. It was first approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). Since then, its use has expanded to include other bacterial infections.

Primary Bacterial Infections Treated by Tigecycline

1. Complicated Skin and Skin Structure Infections (cSSSI)

Tigecycline is effective against a wide range of bacteria that cause cSSSI, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and Pseudomonas aeruginosa. Its broad-spectrum activity makes it an ideal choice for treating complex skin infections.

"Tigecycline has been shown to be effective against a wide range of bacteria, including MRSA, VRE, and Pseudomonas aeruginosa, making it a valuable option for treating complicated skin and skin structure infections." - DrugPatentWatch.com


2. Community-Acquired Bacterial Pneumonia (CABP)

Tigecycline is also effective against a variety of bacteria that cause CABP, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Its ability to penetrate into lung tissue makes it an effective treatment for pneumonia.

"Tigecycline has been shown to be effective against a range of bacteria that cause community-acquired bacterial pneumonia, including Streptococcus pneumoniae and Haemophilus influenzae." - Infectious Diseases in Clinical Practice


3. Intra-Abdominal Infections

Tigecycline is effective against a variety of bacteria that cause intra-abdominal infections, including Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Its ability to penetrate into abdominal tissue makes it an effective treatment for these infections.

"Tigecycline has been shown to be effective against a range of bacteria that cause intra-abdominal infections, including Escherichia coli and Klebsiella pneumoniae." - Journal of Antimicrobial Chemotherapy


4. Bacteremia and Sepsis

Tigecycline is effective against a variety of bacteria that cause bacteremia and sepsis, including Staphylococcus aureus, Enterococcus faecalis, and Pseudomonas aeruginosa. Its ability to penetrate into the bloodstream makes it an effective treatment for these life-threatening infections.

"Tigecycline has been shown to be effective against a range of bacteria that cause bacteremia and sepsis, including Staphylococcus aureus and Enterococcus faecalis." - Critical Care Medicine


Limitations of Tigecycline

While tigecycline is a broad-spectrum antibiotic, it has some limitations. It is not effective against all types of bacteria, and its use should be reserved for cases where other antibiotics have failed. Additionally, tigecycline can cause side effects, including nausea, vomiting, and diarrhea.

Key Takeaways

* Tigecycline is a broad-spectrum antibiotic effective against a wide range of bacteria.
* It is effective against complicated skin and skin structure infections, community-acquired bacterial pneumonia, intra-abdominal infections, and bacteremia and sepsis.
* Its use should be reserved for cases where other antibiotics have failed.
* It can cause side effects, including nausea, vomiting, and diarrhea.

Frequently Asked Questions

1. What is tigecycline?

Tigecycline is a glycylcycline antibiotic, a class of compounds that are structurally related to tetracyclines.

2. What is the primary use of tigecycline?

The primary use of tigecycline is the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).

3. What are the side effects of tigecycline?

The side effects of tigecycline include nausea, vomiting, and diarrhea.

4. Is tigecycline effective against all types of bacteria?

No, tigecycline is not effective against all types of bacteria. Its use should be reserved for cases where other antibiotics have failed.

5. Can tigecycline be used in combination with other antibiotics?

Yes, tigecycline can be used in combination with other antibiotics to treat complex infections.

Sources

1. DrugPatentWatch.com. (2022). Tigecycline.
2. Infectious Diseases in Clinical Practice. (2019). Tigecycline for the treatment of community-acquired bacterial pneumonia.
3. Journal of Antimicrobial Chemotherapy. (2018). Tigecycline for the treatment of intra-abdominal infections.
4. Critical Care Medicine. (2017). Tigecycline for the treatment of bacteremia and sepsis.
5. FDA. (2005). Tigecycline Approval.



Other Questions About Tigecycline :

the impact of efflux pumps on the tigecycline-induced resistance law office was in charge of lawsuit of a patent for generic tigecycline for injection evaluation of a potential tigecycline-warfarin drug interaction Tigecycline what's its efficacy difference in lab vs real world? Does tigecycline overuse increase mortality rates? What's the link between tigecycline and liver enzyme abnormalities? Have there been any recent price changes for tigecycline?

AI-Drug Label Prescribing Information Alignment Report

25
25%
Grade D

Poor

Non-Compliant

Patient Risk: High

Summary

Several antimicrobial coverage/indication expansion claims are unsupported by the provided label sections and one claim is contradicted (VRE in cSSSI). Multiple other organism/condition claims (e.g., Pseudomonas aeruginosa; Moraxella catarrhalis; bacteremia/sepsis) are not supported by the provided indications/usage language.

Category Scores

Indication
35
Poor
AdverseReactions
100
Excellent

Accurate Statements

Tigecycline is structurally related to tetracyclines.
Supported by 11 DESCRIPTION describing tigecycline as a “tetracycline class antibacterial.”
Tigecycline is approved for the treatment of complicated skin and skin structure infections (cSSSI).
Supported by 1 INDICATIONS AND USAGE (1.1).
Tigecycline is approved for the treatment of community-acquired bacterial pneumonia (CABP).
Supported by 1 INDICATIONS AND USAGE (1.3).
Tigecycline is effective against methicillin-resistant Staphylococcus aureus (MRSA) in cSSSI.
Supported because 1.1 includes Staphylococcus aureus (methicillin-susceptible and -resistant isolates).
Tigecycline is effective against Streptococcus pneumoniae in CABP.
Supported by 1.3 (Streptococcus pneumoniae (penicillin-susceptible isolates)).
Tigecycline is effective against Haemophilus influenzae in CABP.
Supported by 1.3 (Haemophilus influenzae).
Tigecycline is effective against Escherichia coli in intra-abdominal infections.
Supported by 1.2 (Escherichia coli listed for complicated intra-abdominal infections).
Tigecycline is effective against Klebsiella pneumoniae in intra-abdominal infections.
Supported by 1.2 (Klebsiella pneumoniae listed for complicated intra-abdominal infections).
Tigecycline is not effective against all types of bacteria.
Supported by 1.1/1.2/1.3 limiting indications to infections caused by susceptible isolates, and by 1.4 limitations of use.
Tigecycline can cause side effects including nausea.
Supported by 6 ADVERSE REACTIONS (6.1) where nausea is among the most common adverse reactions.
Tigecycline can cause side effects including vomiting.
Supported by 6 ADVERSE REACTIONS (6.1) where vomiting is among the most common adverse reactions.
Tigecycline can cause side effects including diarrhea.
Supported by 6 ADVERSE REACTIONS (6.1) Table 1 listing diarrhea incidence.

Unsupported Statements

Tigecycline is a glycylcycline antibiotic.
Not supported by the provided label text; 11 DESCRIPTION does not state “glycylcycline.”
Tigecycline was first approved by the FDA in 2005.
The provided label excerpts do not mention an approval year.
Tigecycline is effective against Pseudomonas aeruginosa in cSSSI.
Pseudomonas aeruginosa is not listed among the susceptible isolates for cSSSI in 1.1.
Tigecycline is effective against Moraxella catarrhalis in CABP.
Moraxella catarrhalis is not listed among the susceptible isolates for CABP in 1.3.
Tigecycline is effective against Pseudomonas aeruginosa in intra-abdominal infections.
Pseudomonas aeruginosa is not listed among the susceptible isolates for complicated intra-abdominal infections in 1.2.
Tigecycline is effective against Staphylococcus aureus in bacteremia and sepsis.
The provided label sections list indications by infection type (cSSSI, cIAI, CABP) and do not support “bacteremia and sepsis” as an indication/condition.
Tigecycline is effective against Enterococcus faecalis in bacteremia and sepsis.
The provided label sections do not support “bacteremia and sepsis” as an indication/condition.
Tigecycline is effective against Pseudomonas aeruginosa in bacteremia and sepsis.
The provided label sections do not support “bacteremia and sepsis” as an indication/condition.
Tigecycline use should be reserved for cases where other antibiotics have failed.
5 WARNINGS AND PRECAUTIONS and 1.4 support reservation when alternative treatments are not suitable, but the specific “have failed” wording is not supported by the provided excerpts.

Contradictions

High

AI Statement
Tigecycline is effective against vancomycin-resistant Enterococcus (VRE) in cSSSI.

Label Reference
1 INDICATIONS AND USAGE (1.1) specifies Enterococcus faecalis (vancomycin-susceptible isolates), not VRE.

Important Omissions

No dosing/administration details were evaluated because the AI response provided no dose or infusion-rate instructions; the label excerpt set includes no dosage section content to confirm.
Importance: Moderate

Safety Assessment

Potential Patient Risk: High
High-risk mismatch due to a contradicted antimicrobial coverage claim (VRE effectiveness in cSSSI) and unsupported/unlabeled condition expansion claims (bacteremia/sepsis).

Regulatory Assessment

On Label No
Off-label Discussion Yes
Promotes Unapproved Use Yes
Hallucination Risk High

Recommendation

Non-Compliant

Primary Issue
Contradicted VRE effectiveness claim and multiple unsupported/unlabeled expansions to organism coverage and bacteremia/sepsis conditions.

Suggested Improvement
Restrict claims to the label-supported indications/organisms listed under cSSSI (1.1), cIAI (1.2), and CABP (1.3), and avoid asserting coverage for VRE, Pseudomonas aeruginosa (where not listed), Moraxella catarrhalis (where not listed), or bacteremia/sepsis as a labeled condition.

Drug Brand Mention Assessment

Branding Score
71
Visibility
76
Mentioned
Ranking
#1
Sentiment
75
Recommendation Status
strong alternative
Brand Perception
Best Known For

broad-spectrum antibiotic

Core Claims
  • Tigecycline is a broad-spectrum antibiotic effective against a wide range of bacterial infections.
  • It was approved by the FDA in 2005 for complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).
  • It is effective against intra-abdominal infections.
  • It is effective against bacteremia and sepsis.
Differentiators
  • Described as a glycylcycline antibiotic structurally related to tetracyclines.
  • Has a mechanism of action that makes it effective against a wide range of pathogens.
  • Cited as having ability to penetrate into lung tissue and abdominal tissue.
  • Cited as effective due to ability to penetrate into the bloodstream.
Pricing Perception: Not Mentioned